Tag:
Labopharm
Latest Headlines
Latest Headlines
Patent cliff could create need for novel delivery tech
As blockbusters go off patent and generics companies scramble to compete, novel drug delivery tech could be the difference-maker in the marketplace.
Paladin acquiring Labopharm in $20M deal
Paladin Labs has struck a deal to buy Labopharm in a deal that values the biotech at a bit more than $20 million. Paladin is paying 28.5 cents a share, a significant premium over the bargain basement
Labopharm continues strategic review, mulls future of Oleptro
Labopharm said today that it's reviewing options for its assets, technologies and products and considering "potential business combinations that could create value for shareholders." The Canadian
Labopharm slashes staff, pushes strategic review
Just days after CEO James Howard-Tripp skipped from Canada's Labopharm, the biotech says it has pink slipped 38 workers--close to a third of its staff--as it pursues a top-to-bottom strategic review
Labopharm shares jump after FDA approves antidepressant
Shares of Canada's Labopharm jumped after the FDA announced it had approved the company's once-daily antidepressant trazodone after the drug was subjected to a delay. But CEO James Howard-Tripp tells
Labopharm's API supplier gets FDA nod
Another drugmaker has fixed its manufacturing problems and won the FDA's new blessing. Canada's Labopharm announced that its active pharmaceutical ingredient supplier has been cleared by the agency,
API issues delay drug approval
Deficiencies at a manufacturing facility are holding up FDA approval of the antidepressant Trazodone. Labopharm, its maker, says its API manufacturer, Angelini, has said that the FDA concerns are
Labopharm shares tank on late-stage pain failure
Shares of Canada's Labopharm tanked this morning after the developer said that its twice-daily pain med failed to hit its primary endpoint in a late-stage trial, setting up a likely rejection at the
Labopharm hopes high for tramadol despite rejection
The FDA has rejected Labopharm's appeal of the regulators' decision on once-daily tramadol, but kept the door open to an approval. If the company files an analysis that had been requested earlier,
C&L: Bioxel CEO resigns
Bioxel Pharma has announced the resignation of Pascal Delmas as president and CEO. Bioxel also appointed Thomas Warden as vice-president, sales, marketing and regulatory affairs. Denmark's Lundbeck
